Initial data from an ongoing Phase I/II study of HPK1 inhibitor NDI-101150 show clinical benefit in three patients with solid tumours, including one complete response in a patient with renal cell carcinoma. Two patients with pancreatic cancer and renal cell carcinoma, respectively, exhibited prolonged (> six… Read More
Register for the DDW Turning Science into Business Summit, ‘Cancer research opportunities and advances’, to hear insight and expertise from leading figures. It will be hosted by DDW and sponsored by Taconic Biosciences. The event will take place online on 16 November at 7AM… Read More
The latest in the DDW eBook series ‘Immunotherapy: Where are the advances and breakthroughs?‘ is now available for download. This 24-page eBook sponsored by Sino Biological looks at the advances and breakthroughs taking place within immunotherapy. Download this exclusive eBook to learn more about: Advances in cancer… Read More
This 24-page eBook sponsored by Sino Biological looks at the advances and breakthroughs taking place within immunotherapy. Download this exclusive eBook to learn more about: Advances in cancer care: Where are the advances in treatments for triple-negative breast cancer? Drug development: Five years of oncology developments Why immunotherapy is here… Read More
Register for the DDW Turning Science into Business Summit, ‘Cancer research opportunities and advances’, to hear insight and expertise from leading figures. It will be hosted by DDW and sponsored by Taconic Biosciences. The event will take place online on 16 November at 7AM PST /… Read More
This is the latest episode of the free DDW narrated podcast, “Drug discovery success stories”, which covers two articles written for Volume 23, Issue 3 – Summer 2022 of DDW. They are called “Global pharma start-up success stories”, and “Excitement at rectal… Read More
Join DDW’s Megan Thomas and Reece Armstrong with sponsor Taconic Biosciences for the first DDW Turning Science into Business Summit, ‘Cancer research opportunities and advances’, on 16 November at 7AM PDT / 10AM EST / 3PM GMT / 4PM CET. This free 2-hour… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Immunotherapy has taken centre stage this week, with several announcements relating to… Read More
News round-up for 25-29 September by DDW Digital Content Editor Diana Spencer. Immunotherapy has taken centre stage this week, with several announcements relating to regulatory approval, investment and research results for antibody and CAR-T therapies, perhaps most significantly, encouraging early-stage data for the first in vivo… Read More
The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to 4SC’s resminostat (Kinselby) for cutaneous T-cell lymphoma (CTCL). Resminostat is an orally administered class I, IIb and IV histone deacetylase (HDAC) inhibitor that potentially offers an approach to treating different kinds of cancer. The company demonstrated that resminostat is… Read More
Umoja Biopharma has revealed data from an ongoing non-human primate (NHP) study demonstrating effective, durable, and well tolerated in vivo chimeric antigen receptor (CAR) T cell generation using the company’s VivoVec platform. The data include results from the first four NHPs treated in an ongoing study… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week’s headline news features a stem-cell derived Parkinson’s therapy, a monoclonal antibody for… Read More
News round-up for 28 August – 1 September by DDW Digital Content Editor Diana Spencer. This week’s headline news features a stem-cell derived Parkinson’s therapy, a monoclonal antibody for head and neck cancer, an estrogen receptor degrader for breast cancer, a mitochondrial activator for long Covid,… Read More
British techbio Etcembly is coming out of stealth mode, kickstarting the next generation of immunotherapies with a pipeline of T cell receptor (TCR) therapeutics designed using generative AI. The company’s lead therapeutic programme, ETC-101, is the world’s first AI-designed bispecific T cell engager. It targets PRAME, a validated antigen present… Read More
A new immunotherapy candidate has demonstrated a trend for slowing cognitive decline in mild Alzheimer’s disease (AD), potentially offering a more accessible and cost-effective alternative to other immunotherapies. Vaxxinity published the Phase IIa clinical trial data in The Lancet’s eBioMedicine (Volume 94, 104665, August 2023), stating… Read More
Diana Spencer investigates therapies in clinical development for triple-negative breast cancer and asks what future treatments might look like. Triple-negative breast cancer (TNBC) accounts for approximately 15% of all breast cancer cases and is one of the main causes of death in women. However, because these cancers are not driven… Read More
